Novavax (NVAX) shares climbed roughly 16% on October 9, pushing the biotech back toward the upper end of its 52-week range, after regulators in Belgium, Germany, and Portugal approved Sanofi's Phase 3 trial of a combined COVID-influenza vaccine. Phase 3 studies are the late-stage trials regulators typically review when weighing whether a vaccine can reach the market, placing this approval well beyond early-stage testing.

The approvals clear the way for patient recruitment to begin in November. That step would trigger a $125 million milestone payment from Sanofi to Novavax — a contractually defined sum released when a development program hits a specified benchmark — making it the immediate catalyst behind the day's advance. Combination vaccines that pair COVID-19 and influenza protection in a single shot have also become a broader industry objective, with several major vaccine developers pursuing candidates of their own.

A Rally on Firmer Footing Than Last Week

Last week told a very different story. Novavax shares spiked more than 20% on Monday after a suspected plague case in Russia stirred pandemic-related buying, but most of that move reversed on Tuesday. The World Health Organization assessed the public health risk as very low, and traders backed off. Since the COVID-19 pandemic, vaccine developers have repeatedly drawn this kind of outbreak-driven buying.

By contrast, the October 9 advance rests on a concrete regulatory step tied to a dated milestone payment rather than an outbreak scare.

The broader market also provided a supportive backdrop. The S&P 500 rose 0.3% and the Nasdaq Composite gained 0.3% on the day. Notably, other vaccine makers did not follow Novavax higher. Moderna and Pfizer showed no similar moves, indicating a Novavax-specific story rather than a sector-wide shift.

The Royalty Math Behind the Stock

Novavax's business model centers on royalties rather than direct sales. Under its partnership with Sanofi, the company collects royalties in the high-teens to low-20% range on Sanofi's global Nuvaxovid net sales — an arrangement in which revenue scales with the partner's commercial results rather than Novavax's own sales operations.

Beyond the royalty stream, Novavax stands to collect up to $350 million in milestone payments tied to the combination vaccine. A separate $75 million payment is expected in mid-2027, linked to manufacturing technology transfer.

That structure means the day's rally is less about a single headline and more about investors re-pricing the path toward those future payments. The November start of patient recruitment is the next concrete checkpoint on that timeline.

Wall Street Remains Mixed

Analyst views on the stock remain divided. The consensus analyst price target sits at $14, well above current trading levels.

Not every analyst is as upbeat. BofA's Alec Stranahan raised his price target on Novavax to $8 from $7 on October 9 while maintaining an Underperform rating, as part of a Q3 earnings preview for the biotech sector. The new target still implies limited upside from current levels and came alongside similar reviews across BofA's biotech coverage list.

For now, the stock's trajectory is tied directly to the Sanofi trial timeline. The next milestone to watch is whether patient recruitment actually begins in November as planned. Beyond that checkpoint, the royalty stream hinges on Sanofi's global Nuvaxovid sales, leaving trial execution and performance as the two threads to track.

Source: CoinCentral